Literature DB >> 31886566

Systematic analysis of survival-associated alternative splicing signatures in clear cell renal cell carcinoma.

Tao Chen1, Wenzhong Zheng1,2, Jianbo Chen3, Shouren Lin4, Zihao Zou5, Xianxin Li6, Zhengling Tan1.   

Abstract

Alternative splicing (AS) constitutes a major reason for messenger RNA (mRNA) and protein diversity. Increasing studies have shown a link to splicing dysfunction associated with malignant neoplasia. Systematic analysis of AS events in kidney cancer remains poorly reported. Therefore, we generated AS profiles in 533 kidney renal clear cell carcinoma (KIRC) patients in The Cancer Genome Atlas (TCGA) database using RNA-seq data. Then, prognostic models were developed in a primary cohort (N = 351) and validated in a validation cohort (N = 182). In addition, splicing networks were built by integrating bioinformatics analyses. A total of 11 268 and 8083 AS variants were significantly associated with patient overall survival time in the primary and validation KIRC cohorts, respectively, including STAT1, DAZAP1, IDS, NUDT7, and KLHDC4. The AS events in the primary KIRC cohorts served as candidate AS events to screen the independent risk factors associated with survival in the primary cohort and to develop prognostic models. The area under the curve of the receiver-operator characteristic curve for prognostic prediction in the primary and validation KIRC cohorts was 0.84 and 0.82 at 2500 days of overall survival, respectively. In addition, splicing correlation networks revealed key splicing factors (SFs) in KIRC, such as HNRNPH1, HNRNPU, KHDBS1, KHDBS3, SRSF9, RBMX, SFQ, SRP54, HNRNPA0, and SRSF6. In this study, we analyzed the AS landscape in the TCGA KIRC cohort and detected predictors (prognostic) based on AS variants with high performance for risk stratification of the KIRC cohort and revealed key SFs in splicing networks, which could act as underlying mechanisms.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  alternative splicing; kidney renal clear cell carcinoma; prognosis; splicing factors; survival

Mesh:

Substances:

Year:  2019        PMID: 31886566     DOI: 10.1002/jcb.29590

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

Review 1.  Potentials of lncRNA-miRNA-mRNA networks as biomarkers for laryngeal squamous cell carcinoma.

Authors:  Yan Lv; Yanhua Wang; Zhikai Zhang
Journal:  Hum Cell       Date:  2022-10-01       Impact factor: 4.374

2.  Identification of a Set of Genes Improving Survival Prediction in Kidney Renal Clear Cell Carcinoma through Integrative Reanalysis of Transcriptomic Data.

Authors:  Banlai Ruan; Xianzhen Feng; Xueyi Chen; Zhiwei Dong; Qi Wang; Kai Xu; Jinping Tian; Jie Liu; Ziyin Chen; Wenzhen Shi; Man Wang; Lu Qian; Qianshan Ding
Journal:  Dis Markers       Date:  2020-10-13       Impact factor: 3.434

3.  A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma.

Authors:  Yingkun Xu; Xiunan Li; Yuqing Han; Zilong Wang; Chenglin Han; Ningke Ruan; Jianyi Li; Xiao Yu; Qinghua Xia; Guangzhen Wu
Journal:  PPAR Res       Date:  2020-09-22       Impact factor: 4.964

4.  LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia.

Authors:  Chao Guo; Ya-Yue Gao; Qian-Qian Ju; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li
Journal:  BMC Cancer       Date:  2020-09-03       Impact factor: 4.430

5.  Systematic Analysis of Alternative Splicing Landscape in Pancreatic Adenocarcinoma Reveals Regulatory Network Associated with Tumorigenesis and Immune Response.

Authors:  Jiahua Lu; Shenyu Wei; Jianying Lou; Shengyong Yin; Lin Zhou; Wu Zhang; Shusen Zheng
Journal:  Med Sci Monit       Date:  2020-07-24

6.  Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.

Authors:  Zhen-Duo Shi; Lin Hao; Xiao-Xiao Han; Zhuo-Xun Wu; Kun Pang; Yang Dong; Jia-Xin Qin; Guang-Yue Wang; Xuan-Ming Zhang; Tian Xia; Qing Liang; Yan Zhao; Rui Li; Shao-Qi Zhang; Jun-Hao Zhang; Jian-Gang Chen; Gong-Cheng Wang; Zhe-Sheng Chen; Cong-Hui Han
Journal:  Mol Cancer       Date:  2022-02-07       Impact factor: 27.401

7.  Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia.

Authors:  Peng Jin; Yun Tan; Wei Zhang; Junmin Li; Kankan Wang
Journal:  Neoplasia       Date:  2020-07-09       Impact factor: 5.715

8.  Genome-Wide Analysis of Methylation-Driven Genes and Identification of an Eight-Gene Panel for Prognosis Prediction in Breast Cancer.

Authors:  Yanshen Kuang; Ying Wang; Wanli Zhai; Xuning Wang; Bingdong Zhang; Maolin Xu; Shaohua Guo; Mu Ke; Baoqing Jia; Hongyi Liu
Journal:  Front Genet       Date:  2020-04-21       Impact factor: 4.599

9.  Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy.

Authors:  Jinhui Liu; Yuanyuan Wang; Jian Yin; Yan Yang; Rui Geng; Zihang Zhong; Senmiao Ni; Wen Liu; Mulong Du; Hao Yu; Jianling Bai
Journal:  J Oncol       Date:  2022-01-12       Impact factor: 4.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.